| | | | | | |
| | Nine Months Ended |
| | September 30, |
(in thousands) | | 2021 | | 2020 |
Operating activities: | | | | | | |
Net income | | $ | 1,000 | | $ | 12,323 |
Adjustments to reconcile net income to net cash provided by operating activities | | | | | | |
Bad debt (recovery) expense | | | (1,186) | | | 3,041 |
Depreciation and amortization expense | | | 21,989 | | | 18,167 |
Amortization of debt issuance costs | | | 221 | | | 211 |
Accretion of acquisition liabilities | | | — | | | 36 |
Deferred taxes | | | (4,572) | | | (3,912) |
Stock-based compensation expense | | | 12,100 | | | 3,561 |
Interest expense (income) | | | 130 | | | (36) |
Change in fair value of contingent consideration | | | 57 | | | (949) |
Offering costs | | | 21,797 | | | 1,852 |
Other | | | 661 | | | 742 |
Changes in operating assets and liabilities net of effect of business combinations | | | | | | |
Trade receivables | | | 690 | | | (11,633) |
Prepaid expenses and other current assets | | | 4,590 | | | (3,457) |
Other non-current assets | | | (162) | | | (9) |
Trade payables | | | 425 | | | 1,881 |
Accrued expenses | | | (684) | | | 2,081 |
Other current liabilities | | | 2,747 | | | (7,143) |
Other non-current liabilities | | | (1,369) | | | 1,082 |
Net cash provided by operating activities | | | 58,434 | | | 17,838 |
Investing activities: | | | | | | |
Purchase of property, plant and equipment | | | (5,499) | | | (6,545) |
Acquisition of business, net of cash acquired | | | (24,323) | | | — |
Net cash (used in) investing activities | | | (29,822) | | | (6,545) |
Financing activities: | | | | | | |
Payments of long-term debt | | | (22,000) | | | (563) |
Deferred payment related to Leiki acquisition | | | — | | | (2,033) |
Deferred payment related to Zentrick acquisition | | | (50) | | | (50) |
Payment of contingent consideration related to Zentrick acquisition | | | — | | | (601) |
Proceeds from common stock issued upon exercise of stock options | | | 5,514 | | | 383 |
Proceeds from common stock issued under employee purchase plan | | | — | | | 425 |
Proceeds from issuance of common stock upon initial public offering | | | 269,390 | | | — |
Proceeds from issuance of common stock in connection with concurrent private placement | | | 30,000 | | | — |
Payments related to offering costs | | | (21,797) | | | (1,230) |
Capital lease payments | | | (1,222) | | | (1,242) |
Shares repurchased for settlement of employee tax withholdings | | | (1,802) | | | — |
Net cash provided by (used in) financing activities | | | 258,033 | | | (4,911) |
Effect of exchange rate changes on cash and cash equivalents and restricted cash | | | (173) | | | (38) |
Net increase in cash, cash equivalents, and restricted cash | | | 286,472 | | | 6,344 |
Cash, cash equivalents, and restricted cash - Beginning of period | | | 33,395 | | | 11,342 |
Cash, cash equivalents, and restricted cash - End of period | | $ | 319,867 | | $ | 17,686 |
| | | | | | |
Cash and cash equivalents | | | 319,825 | | | 17,289 |
Restricted cash (included in prepaid expenses and other current assets on the Condensed Consolidated Balance Sheets) | | | 42 | | | 397 |
Total cash and cash equivalents and restricted cash | | $ | 319,867 | | $ | 17,686 |
Supplemental cash flow information: | | | | | | |
Cash paid for taxes | | | 5,586 | | | 14,901 |
Cash paid for interest | | | 580 | | | 2,692 |
Non-cash investing and financing activities: | | | | | | |
Conversion of Series A preferred stock to common stock in connection with the initial public offering | | | 610 | | | — |
Treasury stock reissued upon the conversion of Series A preferred stock to common stock | | | 260,686 | | | — |
Acquisition of equipment under capital lease | | | 1,518 | | | 973 |
Capital assets financed by accounts payable | | | 41 | | | 1,313 |
Offering costs included in accounts payable and accrued expense | | | — | | | 772 |